CONMED Financial Statements (CNMD)
|
|
Report date
|
|
|
22.02.2021 |
22.02.2022 |
21.02.2023 |
31.12.2023 |
28.02.2024 |
|
31.10.2024 |
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
862.5 |
1 011 |
1 045 |
1 245 |
1 241 |
|
1 286 |
Operating Income, bln rub |
|
|
-27.0 |
37.8 |
70.1 |
137.2 |
130.8 |
|
188.2 |
EBITDA, bln rub |
? |
|
113.6 |
158.4 |
7.80 |
209.1 |
182.2 |
|
228.7 |
Net profit, bln rub |
? |
|
9.52 |
62.5 |
-80.6 |
64.5 |
64.5 |
|
131.7 |
|
OCF, bln rub |
? |
|
64.5 |
111.8 |
33.4 |
143.7 |
125.3 |
|
180.0 |
CAPEX, bln rub |
? |
|
13.0 |
14.9 |
21.8 |
0.000 |
19.0 |
|
13.9 |
FCF, bln rub |
? |
|
51.5 |
96.9 |
11.6 |
143.7 |
106.3 |
|
166.1 |
Dividend payout, bln rub
|
|
|
22.8 |
23.3 |
24.0 |
0.000 |
24.5 |
|
24.6 |
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
Dividend payout ratio, %
|
|
|
239.8% |
37.2% |
0.00% |
0.00% |
38.0% |
|
18.7% |
|
OPEX, bln rub |
|
|
414.3 |
458.3 |
501.2 |
549.7 |
564.2 |
|
510.3 |
Cost of production, bln rub |
|
|
402.2 |
442.6 |
474.2 |
557.8 |
597.9 |
|
587.7 |
R&D, bln rub |
|
|
40.5 |
43.6 |
47.2 |
52.6 |
52.6 |
|
55.3 |
Interest expenses, bln rub |
|
|
44.1 |
35.5 |
28.9 |
39.8 |
39.8 |
|
37.9 |
|
Assets, bln rub |
|
|
1 752 |
1 766 |
2 298 |
0.000 |
2 300 |
|
2 316 |
Net Assets, bln rub |
? |
|
709.0 |
785.4 |
745.5 |
0.000 |
834.2 |
|
932.9 |
Debt, bln rub |
|
|
775.9 |
684.7 |
1 055 |
0.000 |
991.3 |
|
940.8 |
Cash, bln rub |
|
|
27.4 |
20.8 |
28.9 |
0.000 |
24.3 |
|
38.5 |
Net debt, bln rub |
|
|
748.5 |
663.8 |
1 026 |
0.00 |
967.0 |
|
902.3 |
|
Ordinary share price, rub |
|
|
112.0 |
141.8 |
88.6 |
109.5 |
109.5 |
|
95.0 |
Number of ordinary shares, mln |
|
|
28.6 |
29.2 |
30.0 |
31.5 |
30.7 |
|
30.9 |
|
Market cap, bln rub |
|
|
3 201 |
4 134 |
2 663 |
3 455 |
3 358 |
|
2 932 |
EV, bln rub |
? |
|
3 950 |
4 798 |
3 689 |
3 455 |
4 325 |
|
3 835 |
Book value, bln rub |
|
|
-411 |
-303 |
-752 |
0 |
-622 |
|
-500 |
|
EPS, rub |
? |
|
0.33 |
2.14 |
-2.68 |
2.04 |
2.10 |
|
4.27 |
FCF/share, rub |
|
|
1.80 |
3.32 |
0.39 |
4.56 |
3.47 |
|
5.38 |
BV/share, rub |
|
|
-14.4 |
-10.4 |
-25.0 |
0.00 |
-20.3 |
|
-16.2 |
|
EBITDA margin, % |
? |
|
13.2% |
15.7% |
0.75% |
16.8% |
14.7% |
|
17.8% |
Net margin, % |
? |
|
1.10% |
6.19% |
-7.71% |
5.18% |
5.19% |
|
10.2% |
FCF yield, % |
? |
|
1.61% |
2.34% |
0.43% |
4.16% |
3.17% |
|
5.67% |
ROE, % |
? |
|
1.34% |
7.96% |
-10.8% |
|
7.73% |
|
14.1% |
ROA, % |
? |
|
0.54% |
3.54% |
-3.51% |
|
2.80% |
|
5.69% |
|
P/E |
? |
|
336.4 |
66.1 |
-33.0 |
53.6 |
52.1 |
|
22.3 |
P/FCF |
|
|
62.1 |
42.7 |
229.9 |
24.0 |
31.6 |
|
17.7 |
P/S |
? |
|
3.71 |
4.09 |
2.55 |
2.78 |
2.71 |
|
2.28 |
P/BV |
? |
|
-7.79 |
-13.6 |
-3.54 |
|
-5.40 |
|
-5.87 |
EV/EBITDA |
? |
|
34.8 |
30.3 |
473.0 |
16.5 |
23.7 |
|
16.8 |
Debt/EBITDA |
|
|
6.59 |
4.19 |
131.6 |
0.00 |
5.31 |
|
3.95 |
|
R&D/CAPEX, % |
|
|
311.0% |
293.1% |
216.4% |
|
276.4% |
|
397.7% |
|
CAPEX/Revenue, % |
|
|
1.51% |
1.47% |
2.08% |
0.00% |
1.53% |
|
1.08% |
|
CONMED shareholders |